Interpore downgrades sales, slams "invalid patent" ruling
This article was originally published in Clinica
Spinal implants producer Interpore Cross International was last week reeling from a double volley of bad news. In late March, the company was told by the Central District of California court that a patent held by subsidiary Cross Medical Products (CMP) was invalid, weakening its position in its ongoing patent lawsuit against DePuy Acromed. This suit claimed that DePuy's MOSS-Miami line infringed two CMP patents.
You may also be interested in...
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.
With the pre-GDUFA backlog largely acted upon, the FDA expects ANDA approvals to decrease, but supplement actions to increase in FY 2020 and FY 2021.
February and March inspections deferred unless any are deemed mission critical. China director remains behind as staff evacuate.